MCID: ALL010
MIFTS: 56

Allergic Contact Dermatitis

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Allergic Contact Dermatitis

Summaries for Allergic Contact Dermatitis

PubMed Health : 62 About allergic contact dermatitis: A number of chemical or herbal substances can irritate the skin. Redness, burning or itching are normal skin reactions, for instance, to aggressive cleaning agents. Allergic contact dermatitis (sometimes simply called “contact allergies”) is different, though. Here the immune system overreacts to certain substances – sometimes to very small amounts – that normally wouldn’t cause a reaction. Common examples include certain metals, scents and latex rubber. Contact allergies can lead to severe skin reactions. Unlike with many other kinds of allergies, the reaction doesn’t occur immediately, but after one to three days. And contact allergies develop gradually over a long period of time, as a result of repeated contact with the substance that triggers them. Some people are then no longer able to carry on doing the same kind of work as before.

MalaCards based summary : Allergic Contact Dermatitis, also known as dermatitis, allergic contact, is related to nickel allergic contact dermatitis and palladium allergic contact dermatitis. An important gene associated with Allergic Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Hydrocortisone and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A contact dermititis that is an allergic skin reaction to foreign chemical or substances leading to red, itchy, weepy reaction where the skin has come into contact with a substance that the immune system recognizes as foreign.

KEGG : 36 Allergic contact dermatitis (ACD) is a T-cell mediated skin inflammation caused by repeated skin exposure to contact allergens. Although regarded as a dermatosis that is typically triggered by environmental factors, ACD may affect certain individuals more easily than others. A higher risk for polysensitization has been found for polymorphism in the TNFA (TNFA-308) and IL-16 (IL-16-295 C/C) genes.

Wikipedia : 74 Allergic contact dermatitis (ACD) is a form of contact dermatitis that is the manifestation of an... more...

Related Diseases for Allergic Contact Dermatitis

Diseases related to Allergic Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 nickel allergic contact dermatitis 34.6 SELE IL5 IL4 IL10 IFNG CD4
2 palladium allergic contact dermatitis 34.5 TNF IL1B IL17A IL10 CCL17
3 toxicodendron dermatitis 33.1 TNF SELE ICAM1 CXCL8
4 pustulosis of palm and sole 31.7 TNF IL17A CXCL8
5 ige responsiveness, atopic 31.5 IL5 IL4 IL10 IFNG
6 seborrheic dermatitis 31.3 TNF FLG CD4
7 alopecia 31.1 TNF IL4 IL1B IFNG
8 urticaria 31.0 TNF SELE IL6 IL5 IL4 IL31
9 rosacea 31.0 TNF IL6 IL33 CXCL8
10 latex allergy 30.9 TNF IL5 IL4 FLG
11 herpes zoster 30.8 TNF IL10 IFNG CD4
12 pemphigus 30.8 TNF IL6 IL4 IL10
13 acute generalized exanthematous pustulosis 30.7 IL17A CXCL8
14 chronic ulcer of skin 30.7 TNF IL6 IL1B
15 exanthem 30.7 TNF IL6 IL1B IL10 IFNG CXCL8
16 stevens-johnson syndrome/toxic epidermal necrolysis 30.6 IL5 IFNG CXCR3 CCL22 CCL17
17 metal allergy 30.6 TNF IL4 IL1B IL17A IL10 CD4
18 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IL17A IL10 IFNG
19 irritant dermatitis 30.6 TNF IL6 IL4 IL31 IL1B FLG
20 pulpitis 30.6 TNF IL6 IL1B CXCL8
21 tuberculoid leprosy 30.6 IL10 IFNG CD4
22 actinic prurigo 30.5 TNF SELE IL1B ICAM1
23 laryngitis 30.5 TNF IL6 IL1B
24 scabies 30.5 IL31 IL10 FLG CXCL8 CD4
25 pyoderma 30.4 TNF IL1B CXCL8
26 human immunodeficiency virus type 1 30.4 TNF IL10 IFNG CD4 CCL27
27 arthropathy 30.4 TNF IL6 IL1B IFNG
28 varicose veins 30.3 TNF IL6 ICAM1 CXCL8
29 vasculitis 30.3 TNF SELE IL6 IL17A IL10 ICAM1
30 crohn's colitis 30.3 TNF IL1B IFNG CXCL8
31 mycosis fungoides 30.3 IL5 IL4 IFNG CXCR3 CCR10 CCL22
32 fasciitis 30.3 TNF IL6 IFNG CXCL8
33 blepharitis 30.3 TNF IL6 IL4 IL1B CD4
34 hypereosinophilic syndrome 30.3 IL5 IL4 IL10 IFNG CXCL8 CCL17
35 sarcoidosis 1 30.3 TNF IL1B IFNG ICAM1 CXCR3 CD4
36 erythema multiforme 30.3 TNF IL6 IL5 IL4 IFNG ICAM1
37 dermatitis 30.3 TNF IL6 IL5 IL4 IL31 IL1B
38 folliculitis 30.2 TNF IL5 IL4 IFNG CD4
39 burning mouth syndrome 30.2 TNF IL6 IL1B CXCL8
40 thymoma 30.2 TNF IL6 IL4 IL17A
41 purpura 30.2 TNF IL6 IL4 IL10 IFNG
42 cutaneous t cell lymphoma 30.1 IL5 IL4 IFNG CXCR3 CCR10 CCL17
43 severe acute respiratory syndrome 30.1 TNF IL6 IL10 IFNG CXCL8
44 conjunctivitis 30.1 TNF IL6 IL5 IL4 IL33 IL10
45 tetanus 30.1 TNF IL6 IL5 IL4 IL1B IL10
46 pertussis 30.0 TNF IL6 IL1B IL10 CXCL8
47 allergic hypersensitivity disease 29.9 TNF SELE IL5 IL4 IL33 IL17A
48 influenza 29.9 TNF IL6 IL1B IFNG CXCL8
49 allergic asthma 29.9 IL5 IL4 IL17A IL10 IFNG ICAM1
50 viral hepatitis 29.9 TNF IL6 IL4 IL1B IL10 IFNG

Graphical network of the top 20 diseases related to Allergic Contact Dermatitis:



Diseases related to Allergic Contact Dermatitis

Symptoms & Phenotypes for Allergic Contact Dermatitis

MGI Mouse Phenotypes related to Allergic Contact Dermatitis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CCL17 CCR10 CD4 CXCR3 ICAM1 IFNG
2 cellular MP:0005384 10.29 CCL17 CCR10 CD4 CXCR3 ICAM1 IFNG
3 growth/size/body region MP:0005378 10.27 CCR10 CD4 ICAM1 IFNG IL10 IL17A
4 immune system MP:0005387 10.27 CCL17 CCL22 CCR10 CD4 CXCR3 ICAM1
5 homeostasis/metabolism MP:0005376 10.22 CD4 CXCR3 ICAM1 IFNG IL10 IL17A
6 digestive/alimentary MP:0005381 10.19 CD4 ICAM1 IFNG IL10 IL17A IL33
7 endocrine/exocrine gland MP:0005379 10.18 CCR10 CD4 ICAM1 IFNG IL10 IL17A
8 integument MP:0010771 10.1 CCR10 CD4 ICAM1 IFNG IL10 IL17A
9 mortality/aging MP:0010768 10.1 CCL22 CCR10 CD4 CXCR3 ICAM1 IFNG
10 neoplasm MP:0002006 9.76 CXCR3 ICAM1 IFNG IL10 IL1B IL5
11 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL17A IL33 IL4
12 respiratory system MP:0005388 9.32 CXCR3 IFNG IL10 IL17A IL33 IL4

Drugs & Therapeutics for Allergic Contact Dermatitis

PubMed Health treatment related to Allergic Contact Dermatitis: 62

Allergic skin reactions are usually treated with steroid creams, ointments or solutions. But the main thing to do is avoid contact with the substance that triggers the reaction. Protective gloves and clothing can help here, for instance. A change of career may have to be considered if it isn’t possible to avoid contact with the substance in the workplace. If you are believed to have a work-related contact allergy , it’s a good idea to have your doctor inform your employer’s liability insurance. The insurance will cover certain costs, like the costs of protective measures, if the allergy is recognized as being work-related.

Drugs for Allergic Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Bronopol Approved Phase 4 52-51-7
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5
Povidone Approved Phase 4 9003-39-8
6
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
7 Antitubercular Agents Phase 4
8 Antidotes Phase 4
9 Chelating Agents Phase 4
10 Antioxidants Phase 4
11 Hydrocortisone-17-butyrate Phase 4
12 Hydrocortisone 17-butyrate 21-propionate Phase 4
13 sodium thiosulfate Phase 4
14 Hydrocortisone hemisuccinate Phase 4
15 Gold Sodium Thiosulfate Phase 4
16 Analgesics Phase 4
17 Analgesics, Non-Narcotic Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Antirheumatic Agents Phase 4
20 Anti-Inflammatory Agents, Non-Steroidal Phase 4
21
Petrolatum Approved, Investigational Phase 3 8009-03-8
22
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
23
Silver sulfadiazine Approved, Vet_approved Phase 3 22199-08-2 441244
24 Anti-Infective Agents Phase 3
25 Anti-Infective Agents, Local Phase 3
26 Anti-Bacterial Agents Phase 3
27 Dermatologic Agents Phase 3
28 Emollients Phase 3
29 Antiprotozoal Agents Phase 3
30 Antiparasitic Agents Phase 3
31 Parthenolide Approved, Investigational Phase 2 20554-84-1
32
Bacitracin Approved, Vet_approved Phase 2 1405-87-4 439542 10909430
33
Minoxidil Approved, Investigational Phase 2 38304-91-5 4201
34 Pharmaceutical Solutions Phase 1, Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Phosphodiesterase 4 Inhibitors Phase 2
37 Antihypertensive Agents Phase 2
38 Vasodilator Agents Phase 2
39
Denosumab Approved Phase 1 615258-40-7
40
Squaric acid dibutyl ester Investigational Phase 1 2892-62-8
41 Immunologic Factors Phase 1
42 Immunoglobulins Phase 1
43 Antibodies Phase 1
44 Antibodies, Monoclonal Phase 1
45 Adjuvants, Immunologic Phase 1
46
Betamethasone Approved, Vet_approved 378-44-9 9782
47 Grape Approved
48
Histamine Approved, Investigational 51-45-6 774
49
Prednisolone phosphate Approved, Vet_approved 302-25-0
50
Methylprednisolone Approved, Vet_approved 83-43-2 6741

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
3 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
4 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride allergen patch
5 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
6 The Effects of Dupilumab on Allergic Contact Dermatitis Recruiting NCT03935971 Phase 4 Dupilumab
7 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Terminated NCT03741933 Phase 4 Apremilast 30mg
8 Anti-IL-17 a New Treatment for Contact Dermatititis Unknown status NCT02778711 Phase 3 secukinumab
9 A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic Completed NCT02109718 Phase 3 Open Dressings with Petrolatum Jelly;Silver Sulfadiazine Gauze Dressing Group
10 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
11 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
12 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
13 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
14 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
15 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
16 A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis Recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
17 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
18 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
19 Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects. Completed NCT00141180 Phase 1 CP-481,715
20 Effect of RANKL Inhibition on UV-induced Immunosuppression Completed NCT01978483 Phase 1 Denosumab;Diphenylcyclopropenone;Normal Saline
21 A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 Completed NCT03661541 Phase 1 Squaric Acid Dibutyl Ester
22 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
23 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
24 Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy Unknown status NCT02763722
25 Hand Eczema Trial: A Randomised Clinical Trial of the Effect of Classification and Individual Counselling Among Health Care Workers With Hand Eczema Unknown status NCT01012453
26 Alteration of the microRNA-126 Expression: a Possible Mechanism in Allergic Contact Dermatitis to Nickel Completed NCT04365140
27 Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study Completed NCT03902392
28 Epidemiology and Co-Reactivity of Novel Surfactant Allergens Completed NCT02534441
29 Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study Completed NCT03313232
30 Analysis of Immune Reactions Occurring Upon Administration of Patch Tests and Contact Dermatitis Affected Skin Completed NCT01546298
31 Evaluation of the Clinical Implication of Short Repeated Nickel Exposures Completed NCT03309215
32 Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy Completed NCT01953380
33 Human Repeated Insult Patch Test Completed NCT03474874
34 Skin Prick Test in Healthy Volunteers of Any Sex, to Investigate the Potential Allergy to NeoMatriXTM Wound Matrix Completed NCT03522675
35 Oral Metal Contact Allergy: A Cause of Oral Squamous Cell Carcinoma? Completed NCT00693550
36 A Study to Determine if Tetrix Cream Impedes the Resolution of Experimentally Induced Allergic Contact Dermatitis Completed NCT00643214
37 Medrol® In Contact Dermatitis: A Prospective Study To Assess The Safety And Effectiveness Of Medrol In Contact Dermatitis In Indian Subjects Completed NCT00929981 Tablet Methylprednisolone (4 or 16 mg)
38 Molecular and Cellular Characterization of Spongiotic Dermatitis Completed NCT00371163
39 Quality of Life Assessment Before and After Hyposensitization Treatment in Systemic Nickel Allergy Syndrome Completed NCT03731494
40 Improving Value of Care for Patients With Severe Stasis Dermatitis Completed NCT03022786
41 Contact Allergens Causing Chronic Urticaria in a New England-Area Population Completed NCT00868036
42 Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study Completed NCT02575053
43 Children With Aluminium Contact Allergy: Cutaneous Exposure Study Recruiting NCT04438135
44 Systemic Nickel Allergy Syndrome: Intervention Study for the Assessment of the Dietary Indications Recruiting NCT04432896
45 Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC) Active, not recruiting NCT04240587
46 An Investigator Initiated Study to Evaluate the Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions In Healthy Adult Male Subjects Not yet recruiting NCT03945760 Early Phase 1 Baricitinib;Placebo
47 Real-life Study to Assess the Incidence of Allergic Manifestations and Infectious Episodes in Healthy Term Infants at Risk of Dysbiosis During the First Year of Life Not yet recruiting NCT04182425
48 The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers Not yet recruiting NCT04085705
49 RESTenosis in Patients With Contact ALLergy to Metals Zabrze Study Not yet recruiting NCT03588962
50 Defining a PGE2 Pathway in Regulating Eczema Not yet recruiting NCT04133506 Aspirin 300mg

Search NIH Clinical Center for Allergic Contact Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


methdilazine
Methdilazine hydrochloride
Trimeprazine
trimeprazine tartrate

Cochrane evidence based reviews: dermatitis, allergic contact

Genetic Tests for Allergic Contact Dermatitis

Anatomical Context for Allergic Contact Dermatitis

MalaCards organs/tissues related to Allergic Contact Dermatitis:

40
Skin, Testes, T Cells, Lymph Node, Eye, Monocytes, Endothelial

Publications for Allergic Contact Dermatitis

Articles related to Allergic Contact Dermatitis:

(show top 50) (show all 6702)
# Title Authors PMID Year
1
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 54 61
19818069 2010
2
Filaggrin mutations and allergic contact sensitization. 61 54
18478014 2008
3
Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes. 54 61
17581202 2007
4
Human arylamine N-acetyltransferase 2 polymorphism and susceptibility to allergic contact dermatitis. 61 54
16533241 2006
5
CCL22-induced responses are powerfully enhanced by synergy inducing chemokines via CCR4: evidence for the involvement of first beta-strand of chemokine. 54 61
15714581 2005
6
Th(1)/Th(2) responses to drugs. 54 61
11164989 2001
7
IL-4 enhances keratinocyte expression of CXCR3 agonistic chemokines. 61 54
10903743 2000
8
Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. 61 54
10886512 2000
9
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 61 54
10504443 1999
10
Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). 54 61
10233762 1999
11
IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. 54 61
9886425 1999
12
Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. 61 54
9504244 1998
13
Pentoxifylline in vivo and in vitro down-regulates the expression of the intercellular adhesion molecule-1 in monocytes. 54 61
9155652 1997
14
4A11, a monoclonal antibody recognizing a novel antigen expressed on aberrant vascular endothelium. Upregulation in an in vivo model of contact dermatitis. 61 54
8311112 1994
15
Langerhans' cell expression of the selectin ligand, sialyl Lewis x. 54 61
7512530 1994
16
Effect of various metals on intercellular adhesion molecule-1 expression and tumour necrosis factor alpha production by normal human keratinocytes. 54 61
7864660 1994
17
[Immune mechanisms of atopic dermatitis]. 54 61
7507285 1993
18
Expression of adhesion molecules in early allergic patch test reactions. 54 61
1638065 1992
19
Keratinocyte expression of intercellular adhesion molecule 1 (ICAM-1) correlated with infiltration of lymphocyte function associated antigen 1 (LFA-1) positive cells in evolving allergic contact dermatitis reactions. 61 54
1682230 1991
20
Endothelial leucocyte adhesion molecule-1 (ELAM-1) expression in cutaneous inflammation. 61 54
1706195 1991
21
[Allergic contact dermatitis from a new dentin adhesive system]. 54 61
2151486 1990
22
[Contact dermatitis, due to (di)methacrylates, on the hands of dental personnel]. 61 54
2144665 1990
23
Expression of intercellular adhesion molecule-1 in murine allergic contact dermatitis. 61 54
1983170 1990
24
Adverse cutaneous reaction to diabetic glucose sensors and insulin pumps: Irritant contact dermatitis or allergic contact dermatitis? 61
32212168 2020
25
Allergic contact dermatitis and airborne allergic contact dermatitis from methylchloroisothiazolinone/methylisothiazolinone from occupational and non-occupational exposure: All in one patient. 61
32100299 2020
26
Allergic contact dermatitis in response to ketotifen fumarate contained in eye drops. 61
32064627 2020
27
Allergic contact dermatitis to Cupressus sempervirens resin and cross-reaction with colophonium. 61
32091626 2020
28
Occupational allergic contact dermatitis caused by Solvent Orange 60 in protective gloves. 61
32173872 2020
29
Eczema coxsackium complicating allergic contact dermatitis during treatment with pimecrolimus 1% cream in an adult. 61
32190906 2020
30
Allergic contact dermatitis to 3-O-ethyl-L-ascorbic acid: An underrated allergen in cosmetics? 61
32208530 2020
31
The Importance of Education When Patch Testing. 61
32475513 2020
32
Pitfalls in Patch Testing: Minimizing the Risk of Avoidable False-Negative Reactions. 61
32475507 2020
33
Common Allergens and Considerations When Performing Pediatric Patch Testing. 61
32475510 2020
34
American Contact Dermatitis Society Allergens of the Year 2000 to 2020. 61
32475509 2020
35
Occupational pustular allergic contact dermatitis. 61
32162330 2020
36
Allergic Contact Dermatitis to Fragrances. 61
32475515 2020
37
Allergic contact dermatitis from a depilatory wax. 61
32212172 2020
38
Occupational Contact Dermatitis: Common Occupational Allergens. 61
32475512 2020
39
Plant Associated Irritant & Allergic Contact Dermatitis (Phytodermatitis). 61
32475517 2020
40
Allergic contact dermatitis by Artemisia: Report of two cases. 61
32067232 2020
41
Allergic contact dermatitis from acetophenone azine in a Canadian child. 61
32100303 2020
42
Occupational allergic contact dermatitis (OACD) in a cohort of 458 consecutive dermatitis patients; A case series of 17 patients with OACD. 61
32497697 2020
43
Allergic contact dermatitis caused by topical ophthalmic medications: Keep an eye on it! 61
32495386 2020
44
A Fishy Situation: Allergic Contact Dermatitis of the Fingertips Due to Propyl Gallate. 61
32496277 2020
45
Allergic Contact Dermatitis Caused by an Acrylic Nails Kit for Domestic Use. 61
32496278 2020
46
Occupational allergic contact dermatitis to neem oil used in natural cosmetic. 61
32043597 2020
47
Allergic contact dermatitis of head and neck by propolis contained in a shampoo. 61
32048301 2020
48
Occupational allergic contact dermatitis to Hydrangea spp. in an Italian florist. 61
32065404 2020
49
A case of allergic contact dermatitis to dental bonding materials masked by the use of gloves. 61
32515044 2020
50
German S1 guidelines for the diagnosis and treatment of perianal dermatitis (anal eczema). 61
32469472 2020

Variations for Allergic Contact Dermatitis

Expression for Allergic Contact Dermatitis

Search GEO for disease gene expression data for Allergic Contact Dermatitis.

Pathways for Allergic Contact Dermatitis

Pathways related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 TNF IL6 IL5 IL4 IL33 IL31
2
Show member pathways
13.96 TNF IL6 IL5 IL4 IL1B IL17A
3
Show member pathways
13.73 TNF IL6 IL5 IL4 IL33 IL31
4
Show member pathways
13.67 TNF IL6 IL5 IL4 IL1B IL17A
5
Show member pathways
13.55 TNF IL6 IL5 IL4 IL1B IL17A
6
Show member pathways
13.47 TNF IL6 IL5 IL4 IL33 IL31
7
Show member pathways
13.41 TNF IL6 IL5 IL4 IL1B IL17A
8
Show member pathways
13.12 TNF IL6 IL1B IL10 IFNG CXCL8
9
Show member pathways
13.02 TNF IL6 IL1B ICAM1 CXCL8 CD4
10
Show member pathways
13.01 CXCR3 CXCL8 CD4 CCR10 CCL27 CCL22
11
Show member pathways
12.95 TNF IL6 IL33 IL1B IFNG ICAM1
12
Show member pathways
12.95 TNF IL6 IL5 IL4 IL1B IL17A
13
Show member pathways
12.81 TNF IL6 IL5 IL4 IL1B IL17A
14
Show member pathways
12.8 TNF IL6 IL5 IL4 IL1B IL17A
15
Show member pathways
12.79 TNF IL6 IL33 IL1B CXCL8
16
Show member pathways
12.76 TNF IL6 IL1B IL17A IL10 IFNG
17
Show member pathways
12.71 TNF IL4 IL10 IFNG CD4
18 12.7 TNF IL4 IL1B IL17A IL10 IFNG
19
Show member pathways
12.54 IL6 IL5 IL4 IL10 IFNG
20
Show member pathways
12.52 TNF IL6 IL5 IL4 IL1B IL17A
21
Show member pathways
12.51 TNF IL6 IL10 CXCR3 CXCL8 CCR10
22
Show member pathways
12.49 TNF IL6 IL4 IL1B IFNG ICAM1
23
Show member pathways
12.47 TNF IL6 IL5 IL4 IL1B IL17A
24
Show member pathways
12.43 TNF IL6 IL1B IFNG CXCL8
25 12.4 TNF IL6 ICAM1 CD4
26
Show member pathways
12.4 TNF IL4 IL1B IL10 IFNG
27
Show member pathways
12.38 TNF IL6 IL1B IL10 CCL22 CCL17
28 12.37 TNF IL6 IL1B CXCL8
29 12.37 TNF IL6 IL1B IL10 IFNG
30
Show member pathways
12.36 TNF IL6 IL4 IL1B IFNG CXCL8
31 12.34 TNF IL6 IL1B CXCL8
32 12.32 TNF IL6 IL1B IL10 CXCL8
33 12.31 TNF IL6 IL1B CXCL8
34
Show member pathways
12.28 TNF IL33 IL1B IFNG
35 12.25 TNF IL6 IL4 IL1B IFNG ICAM1
36 12.24 TNF SELE IL1B IFNG ICAM1
37 12.23 TNF IL6 IL5 IL4 IL10 IFNG
38 12.17 TNF IL6 IL1B IL10 CXCL8
39
Show member pathways
12.17 TNF IL6 IL1B IL17A IL10 IFNG
40 12.14 TNF SELE IL6 IL1B ICAM1
41 12.14 TNF IL6 IL1B IL10 IFNG CXCL8
42 12.13 TNF SELE IL6 IL1B ICAM1 CXCL8
43 12.12 TNF IL6 IL5 IL4 IL1B CD4
44 12.11 TNF IL6 IL4 IL1B IL17A IL10
45 12.1 TNF IL6 IL1B IL17A IFNG ICAM1
46
Show member pathways
12.09 IL4 IL1B IFNG CD4
47
Show member pathways
12.08 IL6 IL4 IL1B IL17A IFNG CD4
48 12.06 IL6 IL1B IFNG CXCL8
49 12.05 TNF IL1B ICAM1 CXCL8
50 12.03 SELE IL6 IL5 IL4 IFNG ICAM1

GO Terms for Allergic Contact Dermatitis

Cellular components related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF IL6 IL5 IL4 IL33 IL31
2 external side of plasma membrane GO:0009897 9.63 TNF IL17A ICAM1 CXCR3 CD4 CCR10
3 membrane raft GO:0045121 9.56 TNF SELE ICAM1 CD4
4 extracellular space GO:0005615 9.53 TNF SELE IL6 IL5 IL4 IL33

Biological processes related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.37 IL6 IL5 IL4 IL1B IL10 CXCR3
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.28 TNF IL6 IL4 IL33 IL1B IL17A
3 positive regulation of transcription, DNA-templated GO:0045893 10.17 TNF IL6 IL5 IL4 IL1B IL10
4 positive regulation of gene expression GO:0010628 10.16 TNF IL6 IL4 IL33 IL1B IFNG
5 cell-cell signaling GO:0007267 10.07 IL1B IL17A CCL27 CCL22 CCL17
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.04 TNF ICAM1 CD4 CCL22 CCL17
7 leukocyte migration GO:0050900 10.03 TNF SELE IL1B ICAM1
8 positive regulation of protein phosphorylation GO:0001934 10.03 TNF IL1B IFNG CD4
9 response to lipopolysaccharide GO:0032496 10.02 SELE IL1B IL10 ICAM1
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.01 TNF IL6 IL1B ICAM1
11 cellular response to tumor necrosis factor GO:0071356 10 ICAM1 CXCL8 CCL22 CCL17
12 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.97 IL6 IL5 ICAM1 CD4
13 positive regulation of inflammatory response GO:0050729 9.96 TNF IL33 IL1B IFNG
14 cell chemotaxis GO:0060326 9.95 CXCR3 CCR10 CCL27 CCL22
15 calcium-mediated signaling GO:0019722 9.94 SELE CXCR3 CXCL8 CCR10
16 neutrophil chemotaxis GO:0030593 9.93 IL1B CXCL8 CCL22 CCL17
17 cellular response to lipopolysaccharide GO:0071222 9.93 TNF IL6 IL1B IL10 ICAM1 CXCL8
18 regulation of insulin secretion GO:0050796 9.92 TNF IL1B IFNG
19 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.92 TNF IL6 IL4 IFNG
20 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 TNF IL6 IL5 IL1B IL10
21 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
22 humoral immune response GO:0006959 9.91 TNF IL6 IFNG
23 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B IFNG
24 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL4 IL1B CD4
25 monocyte chemotaxis GO:0002548 9.88 IL6 CCL22 CCL17
26 extrinsic apoptotic signaling pathway GO:0097191 9.88 TNF IL33 IFNG
27 positive regulation of interleukin-6 production GO:0032755 9.88 TNF IL6 IL33 IL1B
28 cellular response to interleukin-1 GO:0071347 9.88 IL17A ICAM1 CXCL8 CCL22 CCL17
29 chemotaxis GO:0006935 9.88 CXCR3 CXCL8 CCR10 CCL27 CCL22 CCL17
30 negative regulation of endothelial cell apoptotic process GO:2000352 9.87 IL4 IL10 ICAM1
31 positive regulation of cytokine secretion GO:0050715 9.87 TNF IL10 IFNG
32 microglial cell activation GO:0001774 9.86 TNF IL4 IFNG
33 negative regulation of neurogenesis GO:0050768 9.86 TNF IL6 IL1B
34 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG ICAM1
35 inflammatory response GO:0006954 9.85 TNF SELE IL6 IL5 IL1B IL17A
36 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.84 TNF IL6 IL17A
37 positive regulation of interleukin-6 secretion GO:2000778 9.84 TNF IL1B IL17A IFNG
38 positive regulation of osteoclast differentiation GO:0045672 9.83 TNF IL17A IFNG
39 chemokine-mediated signaling pathway GO:0070098 9.83 CXCR3 CXCL8 CCR10 CCL22 CCL17
40 positive regulation of glial cell proliferation GO:0060252 9.81 TNF IL6 IL1B
41 astrocyte activation GO:0048143 9.8 TNF IL1B IFNG
42 positive regulation of JAK-STAT cascade GO:0046427 9.8 TNF IL6 IL5 IL10
43 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.79 TNF IL1B IFNG
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.78 TNF IL1B IL10
45 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.77 TNF IL6 ICAM1
46 positive regulation of immunoglobulin secretion GO:0051024 9.76 IL6 IL5 IL33
47 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.75 IL4 IL10
48 response to molecule of bacterial origin GO:0002237 9.75 IL10 CXCL8
49 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
50 negative regulation of lipid storage GO:0010888 9.74 TNF IL6

Molecular functions related to Allergic Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 TNF SELE IL6 IL5 IL4 IL33
2 cytokine activity GO:0005125 9.47 TNF IL6 IL5 IL4 IL33 IL31
3 growth factor activity GO:0008083 9.46 IL6 IL5 IL4 IL10
4 chemokine activity GO:0008009 9.26 CXCL8 CCL27 CCL22 CCL17

Sources for Allergic Contact Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....